Safety and Immunogenicity of P27A, a novel candidate blood-stage malaria vaccine, in malaria exposed African adults

Objectives

To assess the safety and immunogenicity of P27A with Alhydrogel or GLA-SE in healthy non-exposed European adults and exposed African adults.

It will be a phase Ia/Ib clinical trial with a rapid assessment of safety in Switzerland before proceeding with a more detailed investigation of the best antigen and adjuvant dose in an endemic population.